查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1667938

分叉病变市场 - 全球产业规模、份额、趋势、机会和预测，按应用细分（週边、冠状动脉）、按地区、竞争情况，2020-2030 年预测

Bifurcation Lesions Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Application (Peripheral, Coronary), By Region, Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球分叉病变市场价值为 27.6 亿美元，预计到 2030 年将达到 40.2 亿美元，复合年增长率为 6.43%。

市场概况
预测期 2026-2030
2024 年市场规模 27.6 亿美元
2030 年市场规模 40.2 亿美元
2025-2030 年复合年增长率 6.43%
成长最快的领域 週边设备
最大的市场 北美洲

全球分叉病变市场涉及医疗设备、程序和疗法，旨在解决血管（特别是冠状动脉）分叉病变的挑战。这些病变会限制血流，导致心血管併发症。

主要市场驱动因素

心血管疾病盛行率上升

主要市场挑战

分叉病变治疗的复杂性

监管和报销障碍

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第五章：全球分叉病变市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依应用（週边、冠状动脉）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第 6 章：北美分叉病变市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 加拿大
    • 墨西哥

第 7 章：欧洲分叉病变市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 英国
    • 义大利
    • 法国
    • 西班牙

第 8 章：亚太地区分叉病变市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：南美洲分叉病变市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲分叉病变市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 沙乌地阿拉伯
    • 阿联酋
    • 科威特
    • 土耳其
    • 埃及

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 最新动态
  • 产品发布
  • 合併与收购

第 13 章：全球分叉病变市场：SWOT 分析

第 14 章：竞争格局

  • Boston Scientific Corp.
  • Abbott Laboratories Inc.
  • Cardinal Health Inc.
  • Medtronic Plc
  • CR Bard, Inc.(Becton, Dickinson and Company)
  • Johnson & Johnson Services, Inc.
  • Spectranetics Corp (Philips Healthcare)
  • Terumo Medical Corp.
  • Poseidon Medical Inc.

第 15 章：策略建议

第16章 调査会社について・免责事项

简介目录
Product Code: 22390

Global Bifurcation Lesions Market was valued at USD 2.76 billion in 2024 and is expected to reach USD 4.02 Billion in the forecast period with a CAGR of 6.43% through 2030. The Global Bifurcation Lesions Market encompasses a specialized segment of the medical industry focused on the diagnosis and treatment of bifurcation lesions, which occur when a major artery divides into two smaller branches.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.76 Billion
Market Size 2030USD 4.02 Billion
CAGR 2025-20306.43%
Fastest Growing SegmentPeripheral
Largest MarketNorth America

The Global Bifurcation Lesions Market deals with medical devices, procedures, and therapies aimed at addressing the challenges posed by bifurcation lesions in blood vessels, particularly in coronary arteries. These lesions can restrict blood flow, leading to cardiovascular complications.

Key Market Drivers

Increasing Cardiovascular Disease Prevalence

The increasing prevalence of cardiovascular diseases (CVDs) serves as a significant market driver propelling the growth of the Global Bifurcation Lesions Market. Cardiovascular diseases, encompassing conditions like coronary artery disease, heart attacks, and angina, are a leading cause of morbidity and mortality globally. The World Health Organization (WHO) reports that CVDs are responsible for over 17 million deaths annually, making them the leading cause of death worldwide. As lifestyles become more sedentary, diets less healthy, and populations age, the burden of CVDs is projected to continue increasing. Bifurcation lesions are a subset of cardiovascular conditions in which plaque buildup or blockages occur at the junctions where major arteries split into smaller branches. Such lesions can lead to severe complications, including heart attacks and reduced blood flow to vital organs. As the prevalence of CVDs increases, so does the incidence of bifurcation lesions, driving the demand for specialized treatments. According to Centers for Disease Control and Prevention, Heart disease is the leading cause of death for both men and women, as well as for individuals across most racial and ethnic groups. Every 33 seconds, someone dies from cardiovascular disease. In 2022 alone, heart disease was responsible for 702,880 deaths, accounting for roughly one in every five deaths.

Key Market Challenges

Complexity of Bifurcation Lesion Treatment

Bifurcation lesions pose a unique set of challenges due to the branching of blood vessels. These complexities include variable lesion morphologies, side branch ostial stenosis, and the risk of restenosis at the bifurcation point. Treating these lesions requires specialized techniques, tools, and stents, which can be challenging for healthcare providers. Additionally, the need for expert knowledge and training in bifurcation lesion management can limit the number of physicians who can effectively perform these procedures, potentially slowing down market growth.

Regulatory and Reimbursement Hurdles

Medical devices and procedures in the cardiovascular field, including those used for bifurcation lesion treatment, are subject to stringent regulatory requirements and approvals. Obtaining regulatory clearance or approval can be a time-consuming and costly process. Furthermore, reimbursement policies vary by region, and reimbursement challenges can affect the adoption of newer and more advanced technologies. Limited or delayed reimbursement for these procedures can discourage healthcare providers from offering them, which can hinder market expansion.

Key Market Players

  • Boston Scientific Corp.
  • Abbott Laboratories Inc.
  • Cardinal Health Inc.
  • Medtronic Plc
  • C. R. Bard, Inc (Becton, Dickinson and Company)
  • Johnson & Johnson Services, Inc.
  • Spectranetics Corp (Philips Healthcare)
  • Terumo Medical Corp.
  • Poseidon Medical Inc

Report Scope:

In this report, the Global Bifurcation Lesions Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bifurcation Lesions Market, By Application:

  • Peripheral
  • Coronary

Bifurcation Lesions Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bifurcation Lesions Market.

Available Customizations:

Global Bifurcation Lesions market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bifurcation Lesions Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Peripheral, Coronary)
    • 5.2.2. By Region
    • 5.2.3. By Company (2024)
  • 5.3. Market Map

6. North America Bifurcation Lesions Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Bifurcation Lesions Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
    • 6.3.2. Canada Bifurcation Lesions Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
    • 6.3.3. Mexico Bifurcation Lesions Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application

7. Europe Bifurcation Lesions Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Bifurcation Lesions Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
    • 7.3.2. United Kingdom Bifurcation Lesions Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
    • 7.3.3. Italy Bifurcation Lesions Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
    • 7.3.4. France Bifurcation Lesions Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
    • 7.3.5. Spain Bifurcation Lesions Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application

8. Asia-Pacific Bifurcation Lesions Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Bifurcation Lesions Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
    • 8.3.2. India Bifurcation Lesions Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
    • 8.3.3. Japan Bifurcation Lesions Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
    • 8.3.4. South Korea Bifurcation Lesions Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
    • 8.3.5. Australia Bifurcation Lesions Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application

9. South America Bifurcation Lesions Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Bifurcation Lesions Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
    • 9.3.2. Argentina Bifurcation Lesions Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
    • 9.3.3. Colombia Bifurcation Lesions Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application

10. Middle East and Africa Bifurcation Lesions Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Bifurcation Lesions Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
    • 10.3.2. Saudi Arabia Bifurcation Lesions Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
    • 10.3.3. UAE Bifurcation Lesions Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
    • 10.3.4. Kuwait Bifurcation Lesions Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Application
    • 10.3.5. Turkey Bifurcation Lesions Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Application
    • 10.3.6. Egypt Bifurcation Lesions Market Outlook
      • 10.3.6.1. Market Size & Forecast
        • 10.3.6.1.1. By Value
      • 10.3.6.2. Market Share & Forecast
        • 10.3.6.2.1. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Bifurcation Lesions Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Boston Scientific Corp.
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Key Personnel
    • 14.1.5. SWOT Analysis
    • 14.1.6. Financials (As Reported)
  • 14.2. Abbott Laboratories Inc.
  • 14.3. Cardinal Health Inc.
  • 14.4. Medtronic Plc
  • 14.5. C. R. Bard, Inc.(Becton, Dickinson and Company)
  • 14.6. Johnson & Johnson Services, Inc.
  • 14.7. Spectranetics Corp (Philips Healthcare)
  • 14.8. Terumo Medical Corp.
  • 14.9. Poseidon Medical Inc.

15. Strategic Recommendations

16. About Us & Disclaimer